Drug Trial Radar · NCT05327010
Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
88
Planned (sponsor's estimate)
Start
Nov 14, 2022
Primary completion
Dec 31, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Apr 14, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II trial tests whether ZEN003694 (ZEN-3694) in combination with talazoparib works to shrink tumors in patients with solid tumors that are unlikely to be cured or controlled with treatment and that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Another aim of this study is to find out if, and how, patients' genes influence their response to this specific drug combination. For this part of the study, investigators will run tests using samples of patients' tumor tissue and blood that will be collected during the study. ZEN-3694 is an inhibitor of a family of proteins called the bromodomain and extra-terminal (BET). It may prevent the growth of tumor cells that overproduce BET protein. Talazoparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Genes are pieces of the DNA code that individuals inherit from their parents. Some genes work to protect against cancer by correcting damage that can occur in the DNA when cells divide. BRCA1 and BRCA2 are two examples of these types of genes, and they are called tumor-suppressor genes. For example, if a person has a mutation in a BRCA1/2 gene they have a greatly increased risk of developing breast and ovarian cancer because their cells may no longer be able to completely repair damaged DNA. It is the accumulation of DNA damage which causes a cell to change into a cancerous cell. Other genes are also involved in this process, and these are called DNA damage repair genes. The KRAS mutation is a change in a protein in normal cells. Normally KRAS serves as an information hub for signals in the cell that lead to cell growth, but when there is a mutation in KRAS it signals too much and cells grow without being told to, which causes cancer. Combination therapy with ZEN-3694 and talazoparib may be effective at slowing or stopping tumor growth in patients with advanced cancer.
Conditions
- Advanced Malignant Solid Neoplasm
- Metastatic Malignant Solid Neoplasm
- Unresectable Malignant Solid Neoplasm
Interventions
BET Bromodomain Inhibitor ZEN-3694Drug
Given PO
Biopsy ProcedureProcedure
Undergo tumor biopsy
Biospecimen CollectionProcedure
Undergo blood sample collection
Diagnostic Imaging TestingProcedure
Undergo diagnostic imaging
TalazoparibDrug
Given PO
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rate (ORR)Time frame: From initiation of treatment to first response
Locations
35 sites in 1 country. Site status is shown where the registry gives one.
City of Hope Comprehensive Cancer Center
Duarte, California
City of Hope at Irvine Lennar
Irvine, California
UC San Diego Moores Cancer Center
La Jolla, California
Keck Medicine of USC Koreatown
Los Angeles, California
Los Angeles General Medical Center
Los Angeles, California
USC / Norris Comprehensive Cancer Center
Los Angeles, California
USC Norris Oncology/Hematology-Newport Beach
Newport Beach, California
University of California Davis Comprehensive Cancer Center
Sacramento, California
UC San Diego Medical Center - Hillcrest
San Diego, California
UCHealth University of Colorado Hospital
Aurora, Colorado
Yale University
New Haven, Connecticut
Smilow Cancer Hospital Care Center-Trumbull
Trumbull, Connecticut
UF Health Cancer Institute - Gainesville
Gainesville, Florida
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia
Northwestern University
Chicago, Illinois
University of Kansas Clinical Research Center
Fairway, Kansas
University of Kansas Cancer Center
Kansas City, Kansas
University of Kansas Cancer Center-Overland Park
Overland Park, Kansas
University of Kansas Hospital-Indian Creek Campus
Overland Park, Kansas
University of Kansas Hospital-Westwood Cancer Center
Westwood, Kansas
University of Kentucky/Markey Cancer Center
Lexington, Kentucky
Ochsner Medical Center Jefferson
New Orleans, Louisiana
National Cancer Institute Developmental Therapeutics Clinic
Bethesda, Maryland
National Institutes of Health Clinical Center
Bethesda, Maryland
University of Kansas Cancer Center - North
Kansas City, Missouri
University of Kansas Cancer Center - Lee's Summit
Lee's Summit, Missouri
University of Kansas Cancer Center at North Kansas City Hospital
North Kansas City, Missouri
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania
University of Texas at Austin
Austin, Texas
University of Texas Medical Branch
Galveston, Texas
UT MD Anderson Cancer Center
Houston, Texas
Huntsman Cancer Institute/University of Utah
Salt Lake City, Utah
University of Virginia Cancer Center
Charlottesville, Virginia
VCU Massey Comprehensive Cancer Center
Richmond, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.